
Bradley J. Monk, MD, FACS, FACOG, discusses the phase 3 KEYNOTE-A18 study of pembrolizumab with chemoradiotherapy for the treatment of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Your AI-Trained Oncology Knowledge Connection!


Bradley J. Monk, MD, FACS, FACOG, discusses the phase 3 KEYNOTE-A18 study of pembrolizumab with chemoradiotherapy for the treatment of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Bradley Monk, MD, FACCOG, FACS, discusses main takeaways from the OUTBACK trial of adjuvant chemotherapy following chemoradiation as primary treatment in patients with locally advanced cervical cancer vs chemoradiation alone.

Bradley J. Monk, MD, FACOG, FACS, on bevacizumab in combination with the vascular disrupting agent fosbretabulin for the treatment of patients with recurrent ovarian, tubal, or peritoneal carcinoma.

Published: March 30th 2015 | Updated: